Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Acquired by Rhumbline Advisers

Rhumbline Advisers grew its holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 10,334.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 46,850 shares of the company’s stock after acquiring an additional 46,401 shares during the period. Rhumbline Advisers owned about 0.08% of Black Diamond Therapeutics worth $218,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bellevue Group AG grew its stake in shares of Black Diamond Therapeutics by 4.9% during the 4th quarter. Bellevue Group AG now owns 8,535,839 shares of the company’s stock worth $23,986,000 after purchasing an additional 400,000 shares during the period. Pale Fire Capital SE acquired a new stake in Black Diamond Therapeutics during the fourth quarter valued at $144,000. Acadian Asset Management LLC increased its holdings in Black Diamond Therapeutics by 13.8% in the first quarter. Acadian Asset Management LLC now owns 170,510 shares of the company’s stock valued at $864,000 after buying an additional 20,616 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of Black Diamond Therapeutics in the first quarter worth about $82,000. Finally, SG Americas Securities LLC acquired a new position in shares of Black Diamond Therapeutics in the second quarter worth about $108,000. Institutional investors and hedge funds own 95.47% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Wedbush reaffirmed an “outperform” rating and set a $16.00 target price on shares of Black Diamond Therapeutics in a research note on Tuesday, September 10th. Raymond James initiated coverage on shares of Black Diamond Therapeutics in a research report on Wednesday, July 31st. They set an “outperform” rating and a $20.00 price objective for the company. Piper Sandler lifted their target price on shares of Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, September 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Black Diamond Therapeutics in a research note on Tuesday, September 24th.

Black Diamond Therapeutics Trading Down 4.1 %

Black Diamond Therapeutics stock opened at $4.23 on Friday. The company has a fifty day simple moving average of $5.54 and a 200-day simple moving average of $5.35. The stock has a market cap of $237.95 million, a P/E ratio of -2.55 and a beta of 2.49. Black Diamond Therapeutics, Inc. has a 12-month low of $1.62 and a 12-month high of $7.66.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.03. As a group, sell-side analysts forecast that Black Diamond Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Black Diamond Therapeutics Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.